No photo of Ian Mills
 

View Scopus Profile

Ian Mills

Professor

 https://orcid.org/0000-0001-5347-5083

  • Room 01.006 - CCRCB

    United Kingdom

19972019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Ian Mills is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 37 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Androgen Receptors Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Androgens Medicine & Life Sciences
Proteins Medicine & Life Sciences
Genes Medicine & Life Sciences
Transcription Factors Medicine & Life Sciences
Prostate Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2016 2019

R2412CNR: YKL40 signalling as a mechanism of relapse following radiotherapy in PTEN-deficient prostate cancer

Armstrong, C., Jain, S., LaBonte Wilson, M., Mills, I., Prise, K. & Waugh, D.

28/06/2017 → …

Project: Research

R6552CNR: Translational Research Network in Prostate Cancer

Mills, I.

01/12/2016 → …

Project: Research

R1757CNR: A new prognostic signature for classification of prostate cancer

Mills, I.

29/03/2017 → 30/06/2019

Project: Research

Research Output 1997 2019

2 Citations (Scopus)

A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients

Movember GAP1 Urine Biomarker Consortium, 20 May 2019, In : BJU International.

Research output: Contribution to journal › Article

Prostatic Neoplasms
Urine
Prostate
RNA
Biopsy
46 Downloads (Pure)

CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation

Itkonen, H. M., Poulose, N., Walker, S. & Mills, I. G., 01 Jul 2019, In : Neoplasia . 21, 7, p. 713-720 8 p.

Research output: Contribution to journal › Article

Open Access
File
Cyclin-Dependent Kinase 9
Prostatic Neoplasms
Fatty Acids
Carnitine
Carnitine O-Palmitoyltransferase
26 Downloads (Pure)

Correction: The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance (Oncogene, (2019), 10.1038/s41388-019-0712-y)

Hepburn, A. C., Steele, R. E., Veeratterapillay, R., Wilson, L., Kounatidou, E. E., Barnard, A., Berry, P., Cassidy, J. R., Moad, M., El-Sherif, A., Gaughan, L., Mills, I. G., Robson, C. N. & Heer, R., 08 May 2019, In : Oncogene. 38, 4425.

Research output: Contribution to journal › Comment/debate

Open Access
File
Oncogenes
Neoplasms
51 Downloads (Pure)

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells

Handle, F., Prekovic, S., Helsen, C., Van den Broeck, T., Smeets, E., Moris, L., Eerlings, R., Kharraz, S. E., Urbanucci, A., Mills, I. G., Joniau, S., Attard, G. & Claessens, F., 24 Sep 2019, In : Scientific Reports. 9, 11 p., 13786.

Research output: Contribution to journal › Article

Open Access
File
Androgen Receptors
Androgens
Prostatic Neoplasms
Castration
docetaxel
1 Citation (Scopus)
47 Downloads (Pure)

High OGT activity is essential for MYC-driven proliferation of prostate cancer cells

Itkonen, H. M., Urbanucci, A., Martin, S. E., Khan, A., Mathelier, A., Thiede, B., Walker, S. & Mills, I. G., 12 Apr 2019, In : Theranostics. 9, 8, p. 2183-2197 15 p.

Research output: Contribution to journal › Article

Open Access
File
Prostatic Neoplasms
Host Factor 1 Protein
Chromatin
Chromatin Immunoprecipitation
Androgens